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Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150 S133ScFv, isolated using phage display technology, had a low
binding afﬁnity (Kd¼ 2.3 x 10-7 M). T-cells were transduced
to express the A2-RMF CAR using MSCV retroviral vector.
However, CAR transduced T-cells bearing the low afﬁnity A2-
RMF ScFv did not demonstrate any binding to the A2-RMF
tetramers, and did not demonstrate any in-vitro cytotoxic
activity against A2+/WT-1+ tumor cell targets. We subse-
quently developed an afﬁnity matured ScFv (Kd¼ 3.08 x 10-9
M) to determine if ScFv binding afﬁnity correlated with
functional activity. T-cells transduced to express CARs
bearing the afﬁnity matured A2-RMF ScFv demonstrated
strong binding to the A2-RMF tetramer in all transduced
cells. The afﬁnity matured A2-RMF CAR modiﬁed T-cells
were able to kill A2+/WT-1+ solid tumor or B cell leukemia
cell lines (29% -40% speciﬁc lysis) at E:T ratios of 50:1 and
20:1, in comparison to 1-4% speciﬁc lysis for HLA A2-/WT-1+
or A2+/WT-1- control tumor cell lines. These data demon-
strate that a TCR-mimic CAR bearing scFv against an A2-RMF
complex, can bind to A2-RMF tetramers and effectively lyse
tumor cell targets co-expressing HLA A2 and WT1 in an HLA
restricted and antigen speciﬁc manner. The results also
suggest that the binding afﬁnity of the antibody is important
for effective functional activity of CAR modiﬁed T-cells
directed against epitopes of self tumor associated antigens.182
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Background: Development of novel (immune) therapies is
of utmost importance to improve survival in relapsed pedi-
atric-AML (acute myeloid leukemia). We aim to develop a
powerful and safe therapy consisting of two potentially
synergistic components: Cord Blood (CB) HSCT and vacci-
nation with CB-derived Wilms Tumor-1 (WT1) mRNA-elec-
troporated dendritic cells (DCs).
Materials & Methods: After isolation, the CD34+ CB stem
cells were cultured using a two-step protocol. First, they
were expanded using a combination of (growth) factors
(Flt3L, SCF, IL-3 and IL-6). Next, the cells were differentiated
towards DCs for one week using medium containing Flt3L,
SCF, GM-CSF, IL-4 and human serum followed by a CYTOMIX
(IL-1beta, IL-6, TNF-alpha and PGE2)-induced maturation for
the last 24 hours. Finally, the CB-DC culture was electro-
porated with WT1-mRNA and their phenotype (cell surface
markers) and function (migration and antigen presentation)
were assessed.
Results: Using the two-step protocol a total cell expansion of
300-500 fold was achieved. Based on surface marker
expression, different DC subsets could be distinguished in
our CB-DC cultures. Since no differences in antigen presen-
tation capacity between the DC subsets were detected, the
whole CB-DC culture was used in all phenotypic and func-
tional assays. The maturation using CYTOMIX induced
upregulation of costimulatory molecules (CD80, CD83 and
CD86) and the chemokine receptor CCR7 on the CB-DCs.
These matured CB-DCs showed enhanced CCR7-dependent
migration towards CCL21 in a trans-well migration assay. The
presentation of WT1 peptides by the CB-DC culture, maturedusing CYTOMIX and electroporated with WT1 mRNA, was
conﬁrmed by the stimulation of T cells expressing a recom-
binant WT-1 peptide speciﬁc TCR. Furthermore, this same
CB-DC culture was able to induce expansion of the WT-1
speciﬁc T cells from their autologous pool of nave T cells in
cord blood. Conclusion: We have developed and tested an in
vitro system for culturing large amounts of DCs from the
CD34+ CB stem cells. Both the phenotypic and functional
data support the use of the whole CB-DC culture as vaccine.
We are currently translating our preclinical protocol to GMP
production of a clinical grade vaccine.183
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Autologous HPC transplants require the collection of sufﬁ-
cient HPCs to ensure engraftment. Inefﬁcient HPC harvests
lead to an over utilization of cytokines (GSCF, Plerixafor),
impose a limitation on storage space and lead to a waste of
resources, material and human. We report the use of an al-
gorithm based on a previously demonstrated positive linear
correlation between peripheral blood HPC dose and the
product HPC dose, to improve the efﬁciency of HPC collection
in patients undergoing autologous HPC harvests.
Methods: HPC collections on 62 consecutive patients were
analyzed. All patients received GCSF priming. Peripheral
blood CD34 (PHPC) counts were enumerated in 31 cases after
the adoption of the predictive algorithm (Cohort 2), and not
in the preceding 31 cases (Cohort 1). PHPC counts were
performed from day 4 of GCSF administration. Product CD34
count was expressed per kg of recipient weight. In Cohort 2
the predetermined algorithm was used to decide on the use
of Plerixafor and timing of collection. Based on peripheral
blood CD 34 counts (cells/mL) patients in Cohort 2 were
grouped into three categories (A:< 7, B:7-10,C:>10). Group A
received Plerixafor prior to collection. For group B the deci-
sion to use Plerixafor was deferred to the physician. Group C
did not receive Plerixafor prior to collection. Further dosing
of Plerixafor was determined by the product CD34 count. The
use of Plerixafor in the two cohorts was assessed retro-
spectively. The association between testing the PHPC count
and the use of Plerixafor was performed using the Chi Square
test. The Wilcoxon Rank Sum test was used to compare the
median number of collections between the two groups. The
proportional difference in patients receiving Plerixafor be-
tween the 2 cohorts was assessed using the Fisher Exact Test.
Results: In Cohort 1 (21 Myeloma and 10 Lymphoma) 80
collections were performed. In Cohort 2 (19 myeloma, 12
Lymphoma) 75 collections were performed. The target
collection was achieved in all patients. Forty three doses of
Plerixafor were administered in 14 patients in Cohort 1, and
21 doses in 6 patients in Cohort 2. The average daily charge
per collection with Plerixafor was $37728.9 and $11406,
without. There was a signiﬁcant association between the use
of a predictive PHPC count and following the algorithm, and
the use of Plerixafor (p ¼ 0.0011). The proportion of collec-
tions preceded by Plerixafor was higher when a PHPC count
was not performed (54% vs 28%, p¼ 0.0009). Proportionately,
